EODData

MEMBERSHIP REGISTER LOG IN

FRA, 30J: IDEAYA BIOSCIENCE DL-01

04 Sep 2025
LAST:

22.40

CHANGE:
 0.40		OPEN:
22.00		HIGH:
22.80		ASK:
0.00		VOLUME:
790
CHG(%):
1.82		PREV:
22.00		LOW:
22.00		BID:
0.00		 

CHART

RECENT END OF DAY PRICES

DateOpenHighLowCloseVolume
04 Sep 2522.0022.8022.0022.40790
03 Sep 2521.6022.0021.6022.00157
02 Sep 2521.0023.0021.0023.0070
01 Sep 2520.8020.8020.8020.80229
29 Aug 2521.2021.6021.2021.60229
28 Aug 2521.4021.4021.4021.40140
27 Aug 2521.2021.2021.2021.20140
26 Aug 2521.2021.6021.2021.6050
25 Aug 2521.6021.8021.6021.60315
22 Aug 2521.2022.0021.2022.00949

COMPANY PROFILE

Name:IDEAYA BIOSCIENCE DL-01
About:IDEAYA Biosciences, Inc., a precision medicine oncology company, discovers and develops targeted therapeutics for patient populations selected using molecular diagnostics in the United States. The company's products in development include IDE196, a protein kinase C inhibitor that is in Phase 2/3 clinical trials for genetically defined cancers having GNAQ or GNA11 gene mutations; IDE397, a methionine adenosyltransferase 2a inhibitor that is in Phase 2 clinical trials for patients with solid tumors having methylthioadenosine phosphorylase gene deletions, such as non-small cell lung (SCLC) and MTAP-deletion urothelial cancer; IDE849, a DLL3 antibody drug conjugate inhibitor that is in Phase 1 clinical trial for the treatment of SCLC and neuroendocrine tumors; IDE275, a Werner Helicase inhibitor that is in Phase 1 clinical trial for patients having tumors with high microsatellite instability; IDE161, a poly ADP-ribose glycohydrolase inhibitor that is in Phase 1/2 clinical trial to treat tumors with homologous recombination deficiency (HRD), and other genetic or molecular signatures; IDE705 (GSK101), a Poly Theta Helicase inhibitor that is in Phase 1 clinical trial for the treatment of tumors with BRCA or other mutations associated with HRD. It also develops preclinical programs, including IDE892, a MTA-cooperative PRMT5 inhibitor; IDE034, a B7H3/PTK7 topo-I-payload bispecific BsADC; and IDE251, a KAT6/7 inhibitor. In addition, the company offers preclinical research programs focused on pharmacological inhibition; DECIPHER dual CRISPR library for synthetic lethality target and biomarker discovery; and INQUIRE chemical library and HARMONY machine-learning engines to enhance its drug discovery platform. The company has strategic alliances with GlaxoSmithKline, Pfizer Inc., Gilead Sciences, Inc., Merck, Biocytogen, Cancer Research UK, and the University of Manchester. IDEAYA Biosciences, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California.
Sector:Healthcare
Industry:Biotechnology
Address:5000 Shoreline Court, South San Francisco, CA, United States, 94080
Website:https://www.ideayabio.com
ISIN:US45166A1025
LEI:549300ULW08F62IJML11

SYMBOL HISTORY

   Add to Watchlist

DOWNLOAD DATA

Download stock quote history quickly and easily in a variety of formats to suit your needs.

  Download

TECHNICAL INDICATORS

MA5:21.96
MA10:21.76
MA20:21.07
MA50:20.14
MA100:18.71
MA200:19.89
STO9:72.73
STO14:75.00
RSI14:58.54
WPR14:-25.00
MTM14:1.80
ROC14:0.09
ATR:0.69
Week High:23.00
Week Low:20.80
Month High:23.00
Month Low:19.10
Year High:34.10
Year Low:12.82
Volatility:49.27